Drug of choice for palliative treatment of pancreatic carcinoma
Correct Answer: Gemcitabine
Description: Ans. is 'b > a & c' i.e. Gemcitabin > Erlotinib & Paclitaxel Treatment for Inoperable pancreatic cancerA) Inoperable locally advanced disease* Approximately 30% of patients present with locally advanced unresectable but nonmetastatic pancreatic carcinoma.* Gemcitabine is used a the treatment of choice for these patients.* The median survival with gemcitabine is 9 months, and patients who respond to or achieve stable disease after 3-6 months of gemcitabine may derive benefit from consolidation radiotherapy.B) Metastatic Disease* Approximately 60% of patients with pancreatic cancer present with metastatic disease.* Gemcitabine is the standard treatment with a median survival of 6 months and a 1-year survival rate of only 20%.* The combination of erlotinib, oral HER1/EGFR tyrosine kinase inhibitor with gemcitabine resulted in an improved 1-year survival compared with gemcitabine alone (23% versus 17%, p = 0.023).* Capecitabine, an oral fluoropyrimidine, has been combined with gemcitabine (GEM-CAP) in a phase III trial that showed an improvement in response rate and progression-free survival over single-agent gemcitabine, but no survival benefit.* A trial in good performance status patients with metastatic pancreatic cancer showed improved survival with the combination of 5FU/FA, irinotecan and oxaliplatin (FOLFIRINOX) compared with gemcitabine, but with increased toxicity. Nab-paclitaxel (Abraxane), an albumin bound nano-particle formulation of paclitaxel, given with gemcitabine also shows promising activity.
Category:
Surgery
Get More
Subject Mock Tests
Practice with over 200,000 questions from various medical subjects and improve your knowledge.
Attempt a mock test nowMock Exam
Take an exam with 100 random questions selected from all subjects to test your knowledge.
Coming SoonGet More
Subject Mock Tests
Try practicing mock tests with over 200,000 questions from various medical subjects.
Attempt a mock test now